Javascript must be enabled to continue!
Pneumococcal Vaccine Response After Exposure to Parasites in Utero, in Infancy, or Mid-Childhood
View through CrossRef
BACKGROUND AND OBJECTIVE:Streptococcus pneumoniae is a leading cause of mortality before age 5, but few studies examine details of childhood response to pneumococcal vaccine in less-developed settings. Although malnutrition, HIV, and concurrent infections can impair response, evidence suggests that chronic parasitic infections can also contribute to poor vaccination results. The objective of this study was to determine whether response to pneumococcal vaccine varied among children either exposed to parasitic infections in utero, previously infected in infancy, or infected at the time of immunization.METHODS:Children from a 2006 to 2010 maternal–infant cohort were eligible for the current study. Children were screened for malaria, schistosomiasis, filariasis, intestinal helminths, and protozoa. Data on in utero exposure and early life infections were linked, and baseline antipneumococcal immunoglobulin G levels and nasopharyngeal carrier status were determined. Participants received decavalent pneumococcal vaccine, and 4 weeks later, serology was repeated to assess vaccine response.RESULTS:A total of 281 children were included. Preimmunity was associated with greater postvaccination increments in anti–pneumococcal polysaccharide immunoglobulin G, especially serotypes 4, 7, 9, 18C, and 19. Present-day growth stunting was independently associated with weaker responses to 1, 4, 6B, 7, 9V, and 19. Previous exposure to Trichuris was associated with stronger responses to 1, 5, 6B, 7, 18C, and 23, but other parasite exposures were not consistently associated with response.CONCLUSIONS:In our cohort, hyporesponsiveness to pneumococcal conjugate vaccine was associated with growth stunting but not parasite exposure. Parasite-related vaccine response deficits identified before age 3 do not persist into later childhood.
American Academy of Pediatrics (AAP)
Title: Pneumococcal Vaccine Response After Exposure to Parasites in Utero, in Infancy, or Mid-Childhood
Description:
BACKGROUND AND OBJECTIVE:Streptococcus pneumoniae is a leading cause of mortality before age 5, but few studies examine details of childhood response to pneumococcal vaccine in less-developed settings.
Although malnutrition, HIV, and concurrent infections can impair response, evidence suggests that chronic parasitic infections can also contribute to poor vaccination results.
The objective of this study was to determine whether response to pneumococcal vaccine varied among children either exposed to parasitic infections in utero, previously infected in infancy, or infected at the time of immunization.
METHODS:Children from a 2006 to 2010 maternal–infant cohort were eligible for the current study.
Children were screened for malaria, schistosomiasis, filariasis, intestinal helminths, and protozoa.
Data on in utero exposure and early life infections were linked, and baseline antipneumococcal immunoglobulin G levels and nasopharyngeal carrier status were determined.
Participants received decavalent pneumococcal vaccine, and 4 weeks later, serology was repeated to assess vaccine response.
RESULTS:A total of 281 children were included.
Preimmunity was associated with greater postvaccination increments in anti–pneumococcal polysaccharide immunoglobulin G, especially serotypes 4, 7, 9, 18C, and 19.
Present-day growth stunting was independently associated with weaker responses to 1, 4, 6B, 7, 9V, and 19.
Previous exposure to Trichuris was associated with stronger responses to 1, 5, 6B, 7, 18C, and 23, but other parasite exposures were not consistently associated with response.
CONCLUSIONS:In our cohort, hyporesponsiveness to pneumococcal conjugate vaccine was associated with growth stunting but not parasite exposure.
Parasite-related vaccine response deficits identified before age 3 do not persist into later childhood.
Related Results
Immunogenicity of Minhai 13-valent pneumococcal polysaccharide conjugate vaccine in experimental mice
Immunogenicity of Minhai 13-valent pneumococcal polysaccharide conjugate vaccine in experimental mice
Diseases caused by pneumococci are a global public health problem. The widespread use of antibiotics has led to a sharp increase in the drug resistance of pneumococci, making resea...
Changes and determinants of pneumococcal vaccine uptake in Ethiopia
Changes and determinants of pneumococcal vaccine uptake in Ethiopia
Abstract
Background:
Pneumococcal pneumonia is one of the most common causes of severe pneumonia and pneumonia-related mortality globally. It is one of the top five causes ...
Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine
Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine
Objective: To review the immurtogenicity, efficacy, and safety of the 13-valent pneumococcal conjugate vaccine (PCV13) for use in pediatric patients. Data Sources: A MEDLINE search...
Effects of Pneumococcal Vaccination in Children Under Five Years of Age in the Democratic Republic of Congo: A Systematic Review
Effects of Pneumococcal Vaccination in Children Under Five Years of Age in the Democratic Republic of Congo: A Systematic Review
Background: In the Democratic Republic of Congo (DRC), the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in 2011 through a three-dose schedule, targeting infants ...
Philosophy and Childhood
Philosophy and Childhood
Philosophy of childhood is an academic field born at least with Heraclitus and his connection between aion (time), pais (child), and basileie (kingdom). There are many ways of unde...
The Status of Rabies Post Exposure Prophylaxis Using Nerve Tissue Anti-Rabies Vaccine in Ethiopia
The Status of Rabies Post Exposure Prophylaxis Using Nerve Tissue Anti-Rabies Vaccine in Ethiopia
The use of anti-rabies vaccine as post-exposure prophylaxis started during the year 1885 and play significant role in preventing rabies cases in humans. Since then, anti-rabies vac...
Attitudes towards COVID-19 vaccination, vaccine hesitancy and intention to take the vaccine
Attitudes towards COVID-19 vaccination, vaccine hesitancy and intention to take the vaccine
Background: The pandemic is at a paradoxical stage, with vaccine roll out initiated but a significantly elevated level of infection and death. Hope for recovery lies in high equita...
Evaluating clinical effectiveness and safety of pneumococcal immunization of infants
Evaluating clinical effectiveness and safety of pneumococcal immunization of infants
According to WHO, pneumococcal infection (PI) is considered one of the most dangerous of all vaccine-preventable diseases and, before vaccination, led to the death of up to 1.6 mil...

